Acute kidney injury
Conditions
Interventions
30mL/min/1.73m2 allocated in group 1
This is a randomized, controlled, blind, three-arm clinical study, each arm being defined based on the previous renal function of each patient Previous renal function was calculated using electronic s
60mL/min/1.73m2 were allocated to the control group
patients with glomerular filtration rate <
and patients with glomerular filtration rate between 30-59mL/min/1.73m2 were allocated in group 2 The expected study sample size is 100 patients. In each arm (control group
group 1 and group 2) 40 patients were randomized in a controlled manner in the control and group 2 groups, and 20 patients in group 1Randomization was performed electronically, in an excel spreadsheet
and 10 people will only receive intravenous hydration with physiological saline solution (1ml/Kg/h) 12h before the procedure and 12h after it Experimental group 2: 20 people with peripheral arterial d
Sponsors
Hospital Geral de Goiania dr Alberto Rassi
Hospital Geral de Goiania dr Alberto Rassi
Eligibility
Inclusion criteria
Inclusion criteria: Hospitalized patients with peripheral arterial occlusive disease requiring contrast-enhanced imaging procedures (diagnostic and/or therapeutic arteriography only). Signed informed consent (ICF) was obtained. Patients of any age. Any gender were eligible. Individuals with normal renal function, defined by an estimated glomerular filtration rate (eGFR)>60mL/min/1.73m², were included in the control group. Patients with impaired renal function consistent with moderate chronic kidney disease (eGFR between 30–59 mL/min/1.73m²) .Severe chronic kidney disease (eGFR < 30 mL/min/1.73m²) were also included
Exclusion criteria
Exclusion criteria: Patients with congestive heart failure. Septic or cardiogenic shock. Patients who used nephrotoxic medications or iodinated contrast in the 48-hour period before the evaluation. Patients with acute kidney injury or chronic kidney disease on dialysis
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Changes in renal function will be evaluated within a period of 1 year, confirmed by laboratory examination, serum dosage of renal biomarkers, from an absolute (greater than 0.5mg/dl) or relative (greater than 25%) elevation of creatinine; and absolute increase greater than 10% in cystatin C, in pre- and post-intervention measurements | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary outcomes are not expected | — |
Countries
Brazil
Contacts
Public ContactDaniel Fernandes
Hospital Geral de Goiania dr Alberto Rassi
Outcome results
None listed